Ralliant Corporation (NYSE:RAL) Short Interest Update

Ralliant Corporation (NYSE:RAL) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 2,784,414 shares, an increase of 32.4% from the November 30th total of 2,102,958 shares. Approximately 2.5% of the company’s stock are short sold. Based on an average trading volume of 1,453,677 shares, the short-interest ratio is currently 1.9 days. Based on an average trading volume of 1,453,677 shares, the short-interest ratio is currently 1.9 days. Approximately 2.5% of the company’s stock are short sold.

Institutional Trading of Ralliant

Several large investors have recently made changes to their positions in RAL. ST Germain D J Co. Inc. purchased a new stake in shares of Ralliant during the 2nd quarter worth about $27,000. Manchester Capital Management LLC acquired a new position in shares of Ralliant during the second quarter worth about $29,000. Westfuller Advisors LLC purchased a new stake in shares of Ralliant in the third quarter worth about $26,000. Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the third quarter valued at about $26,000. Finally, UMB Bank n.a. acquired a new position in Ralliant during the 3rd quarter worth approximately $29,000.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Citigroup raised shares of Ralliant from a “neutral” rating to a “buy” rating and raised their price objective for the company from $53.00 to $61.00 in a research note on Monday, December 8th. Truist Financial started coverage on shares of Ralliant in a report on Friday, December 12th. They issued a “buy” rating and a $62.00 price target for the company. Royal Bank Of Canada raised their price target on Ralliant from $45.00 to $52.00 and gave the stock a “sector perform” rating in a research report on Friday, November 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of Ralliant in a report on Monday. Finally, Morgan Stanley started coverage on shares of Ralliant in a report on Tuesday, September 2nd. They set an “overweight” rating and a $55.00 target price for the company. Six equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $57.89.

Ralliant Price Performance

Shares of Ralliant stock traded down $0.09 on Tuesday, reaching $51.16. The company had a trading volume of 887,669 shares, compared to its average volume of 1,354,990. The company has a current ratio of 1.49, a quick ratio of 1.03 and a debt-to-equity ratio of 0.39. Ralliant has a 1 year low of $40.70 and a 1 year high of $55.08. The firm has a market capitalization of $5.77 billion and a price-to-earnings ratio of 40.28. The firm’s 50-day simple moving average is $47.99.

Ralliant (NYSE:RAL) last posted its earnings results on Wednesday, November 5th. The company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.02. The business had revenue of $529.10 million for the quarter, compared to analysts’ expectations of $519.14 million. Ralliant has set its Q4 2025 guidance at 0.620-0.680 EPS.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 23rd. Shareholders of record on Monday, December 8th were given a $0.05 dividend. This represents a $0.20 annualized dividend and a yield of 0.4%. The ex-dividend date was Monday, December 8th. Ralliant’s dividend payout ratio is currently 15.75%.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.